Share price · BNTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BNTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Aug 2026-8.4%
- 19 Aug 2026+22.0%
Nothing announced by BNTX that day or the session before.
- 21 Apr 2026+6.1%
Nothing announced by BNTX that day or the session before.
- 11 Mar 2026+8.3%
- 10 Mar 2026-17.9%
- 2 Feb 2026-4.3%
Nothing announced by BNTX that day or the session before.
- 21 Jan 2026+11.8%
Nothing announced by BNTX that day or the session before.
- 13 Jan 2026+4.9%
- Day beforeBioNTech: 6-K filing
Share of unusual movement by asset
For each asset, the share of BNTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Trastuzumab pamirtecanevents and moves
| 2 | shown from 8 days |
Pumitamigevents and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 3% |
| Other company news (earnings, financing, releases naming no asset) | — | 37% |
| Sessions with no dated event | — | 61% |
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HER3Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | B7-H3Antibody–drug conjugate | Non-Small Cell Lung CancerMetastatic Castration-Resistant Prostate Cancer | |
| Phase 3 | PD-L1 and VEGF-AMultispecific antibody | Non-Small Cell Lung CancerSmall Cell Lung Cancer | |
| Phase 3 | HER2Antibody–drug conjugate | Breast CancerEndometrial Cancer HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer | |
| Phase 2 | Tumor-associated antigens: MAGE-A3, CLDN6, KK-LC-1, PRAME, MAGE-A4Vaccine | Non-Small Cell Lung Cancer | |
| Phase 2 | TROP2Antibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1/2 | CD40 x 4-1BB (dual)Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | HIV antigensVaccine | HIV | |
| Phase 1 | HIV envelopeMonoclonal antibody | HIV |
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
November 2026 (1)
What to watch
2027 (14)
January 2027 (2)
What to watch
What to watch
May 2027 (2)
June 2027 (1)
July 2027 (2)
August 2027 (2)
November 2027 (1)
2028 (12)
January 2028 (1)
March 2028 (3)
July 2028 (1)
August 2028 (3)
What to watch
What to watch
What to watch
September 2028 (2)
What to watch
October 2028 (1)
November 2028 (1)
What to watch
2029 (8)
January 2029 (2)
April 2029 (2)
August 2029 (1)
What to watch
October 2029 (1)
November 2029 (1)
2030 (5)
February 2030 (1)
June 2030 (1)
What to watch
September 2030 (1)
November 2030 (1)
2031 (4)
February 2031 (2)
What to watch
August 2031 (1)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.3B | $2.4B | $9.0B | $322M$517M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.0B | $2.4B | $10.2B | $180M$225M operating cash flow | report ↗ |
| 2023-FY | $4.1B | $1.9B | $12.9B | —$5.8B operating cash flow | report ↗ |
| 2022-FY | $18.2B | $1.6B | $14.8B | —$14.3B operating cash flow | report ↗ |
| 2021-FY | $22.5B | $1.1B | $1.9B | —$1.1B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 27 sales ($89.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-09 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 36,209 | $95.37 | $3.5M | Form 4 |
| 2026-10-08 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 27,000 | $92.31 | $2.5M | Form 4 |
| 2026-10-07 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 24,000 | $95.86 | $2.3M | Form 4 |
| 2026-10-06 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 21,000 | $96.81 | $2.0M | Form 4 |
| 2026-10-05 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 72,000 | $97.23 | $7.0M | Form 4 |
| 2026-10-02 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 17,000 | $96.72 | $1.6M | Form 4 |
| 2026-10-01 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 17,000 | $97.46 | $1.7M | Form 4 |
| 2026-09-30 | Sahin Ugur · Chief Executive Officer, 10% owner | Open-market sale | 32,000 | $98.12 | $3.1M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 272 reporting institutions held 47.4M shares ($3.6B, 18.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 5,709,240 | $507.4M |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3,793,711 | $337.2M |
| 3 | FLOSSBACH VON STORCH SE | 3,680,315 | $327.1M |
| 4 | Dodge & Cox | 3,676,791 | $326.8M |
| 5 | BlackRock, Inc. | 1,658,153 | $147.4M |
| 6 | BNP PARIBAS FINANCIAL MARKETS | 1,651,789 | $146.8M |
| 7 | Temasek Holdings (Private) Ltd | 1,506,027 | $133.9M |
| 8 | CITADEL ADVISORS LLC | 951,372 | $84.6M |
| 9 | BANK OF AMERICA CORP /DE/ | 903,029 | $80.3M |
| 10 | GSK plc | 889,824 | $79.1M |
| 11 | BAILLIE GIFFORD & CO | 882,572 | $78.4M |
| 12 | FIRST TRUST ADVISORS LP | 839,991 | $74.7M |
| 13 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 783,995 | $69.7M |
| 14 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 670,514 | $59.6M |
| 15 | Long Focus Capital Management, LLC | 624,000 | $55.5M |